Traditionally it is recommended that hyperthyroid patients should be made euthyroid prior to thyroidectomy. However, several small observational studies have reported no increase in adverse events when hyperthyroid patients undergo thyroidectomy. The aim of this study was to assess outcomes following total thyroidectomy in patients who were biochemically hyperthyroid at the time of surgery compared to those who were euthyroid. One hundred and fifty-one eligible patients undergoing thyroidectomy for hyperthyroidism between January 2012 and February 2016 were identified, of whom 57 were hyperthyroid on perioperative blood tests and 94 were euthyroid (comparison group). Primary outcomes were 30-day mortality, increased length of postoperative hospital stay and intraoperative signs consistent with thyrotoxicosis (e.g. heart rate >100 per minute, systolic blood pressure >180 or <60 mmHg, or temperature >38°C). Secondary outcomes were intraoperative beta-blocker use and level of care required postoperatively. Thirty-day mortality was zero. The only significant difference between the two groups was a higher use of intraoperative beta-blockers amongst hyperthyroid patients (28.1% versus 8.5%, P=0.002). Our findings suggest that thyroidectomy for mild to moderate biochemical hyperthyroidism performed by an experienced thyroid surgeon and anaesthetist, is associated with increased intraoperative beta-blocker use but no statistical difference in mortality, length of postoperative stay or intraoperative signs consistent with thyrotoxicosis. While we still recommend attempting to achieve a euthyroid state whenever possible prior to thyroid surgery, mild to moderate degrees of residual biochemical hyperthyroidism when appropriately managed may not be associated with an increase in adverse outcomes.
It has been traditionally recommended that when possible, a euthyroid state is achieved in hyperthyroid patients prior to thyroidectomy 1, 2 . It was believed that hyperthyroid patients were at increased risk of haemodynamic instability as a result of the thyrotoxicosis, exacerbated by the stress of surgery or by surgical manipulation of the thyroid gland. There is limited evidence to support or quantify this risk [3] [4] [5] . Small observational studies have found no increase in adverse events in hyperthyroid patients undergoing thyroidectomy [6] [7] [8] . Furthermore, the risk of thyroidectomy in thyrotoxic patients may be reduced now that surgical practice has largely shifted from the traditional subtotal to near-total or total thyroidectomy. The latter operation is the preferred approach in our institution 9 . A subtotal thyroidectomy involves resection through thyroid tissue and oversewing of the transected edge of the thyroid tissue and is associated with a high rate of recurrent thyrotoxicosis whereas a total thyroidectomy involves complete excision of the thyroid gland 10 . New or exacerbated perioperative thyrotoxicosis is theoretically less likely following total thyroidectomy compared to subtotal, as there is less tissue handling intraoperatively, less postoperative tissue necrosis and no or minimal residual thyroid tissue in situ postoperatively.
Preoperatively, when faced with a hyperthyroid patient, the risk of delaying versus proceeding to surgery is not always clear. By delaying surgery, the patient will remain hyperthyroid for a longer period with the potential for associated complications. There are also social and financial costs for the patient and financial costs for the hospital that result from postponed surgery. Conversely, proceeding to surgery with a thyrotoxic patient carries the theoretical risks of perioperative haemodynamic instability.
At our institution, some patients remain biochemically and/or symptomatically hyperthyroid at the time of presentation for surgery. Reasons for this include antithyroid drug intolerance, medication non-adherence, severity of thyrotoxicosis (i.e. remaining thyrotoxic despite maximally tolerated antithyroid medication) and patients coming from a wide catchment area, often with limited access to tertiary hospital care. After careful review by an experienced anaesthetist and after discussion when needed, with the treating endocrinologist, some of these patients proceed to surgery while still thyrotoxic.
The aim of this study was to assess the outcome of patients undergoing thyroidectomy for hyperthyroidism, comparing those who were biochemically thyrotoxic at the time of surgery with patients who had become euthyroid.
Materials and methods
Ethical approval was obtained (17/CEN/142) and the study was conducted in accordance with the New Zealand National Health Advisory Committee's Ethical Guidelines for Observational Studies, and with permission of the Endocrine and Anaesthetic Departments.
Patients with hyperthyroidism undergoing elective thyroidectomy between January 2012 and February 2016 in Waikato, New Zealand, were identified from hospital coding and an endocrine surgery database. Clinical and laboratory records were reviewed.
Patients were excluded if they had never been hyperthyroid, if the indication for surgery was for suspected malignancy, if no thyroid function tests within ten days of surgery were available, if they were undergoing a second surgery under the same anaesthetic (e.g. cholecystectomy) or if clinical and anaesthetic records were not available for review.
Patients were defined as being thyrotoxic if there was i.e. TSH below the lower limit of assay detection) whereas medically-treated patients with normal thyroid levels or subclinical hyperthyroidism (normal FT3 and FT4 and a low TSH) were considered euthyroid. Thyrotoxicosis severity was arbitrarily classified according to FT3 values into three categories: mild (FT3 6.8-9.9 pmol/l [up to 1.6 times the upper limit reference interval], moderate (FT3 10-19.9 pmol/l [1.6-3 times the upper limit reference interval]) and severe (FT3 >20 pmol/l [>3 times the upper limit of reference interval]). The standard surgical procedure was a total thyroidectomy. Anaesthesia was performed by one of two experienced anaesthetists using a volatile agent, a muscle relaxant, and endotracheal anaesthesia. In addition, one anaesthetist employed a remifentanil infusion intraoperatively, whereas the other used intermittent fentanyl boluses. In all other respects both techniques were similar.
Primary outcomes were 30-day mortality, length of postoperative hospital stay and evidence of intraoperative thyrotoxicosis (defined as one or more of heart rate >100 per minute, systolic blood pressure >180 or <60 mmHg, temperature >38°C). Secondary outcomes were use of intraoperative beta-blocker and level of care postoperatively (standard surgical ward versus high dependency unit [HDU] or intensive care unit).
All statistical analyses were carried out using Stata 13 (Stata Statistical Software: Release 13, StataCorp LLC, College 
Results
Of the 228 patients who underwent thyroidectomy for hyperthyroidism during the study period, 151 met the inclusion criteria. Seven of the 228 patients were excluded due to having a second procedure under the same anaesthetic, while the remainder were excluded because of missing data. Outcome data was reviewed for all 228 patients and none of the excluded patients had an adverse outcome. Of the 151 patients included, 57 (37.7%) remained thyrotoxic while 94 had become euthyroid and were used as the comparison group. The median age for the overall group was 40 (interquartile range 22 [range 13-81]) years and 128 patients (84.8%) were women. Graves' disease was the most common aetiology of the thyrotoxicosis at 76.2%.
As expected, the thyrotoxic group had higher free thyroid hormone levels, a higher American Society of Anesthesiologists physical status score and were more likely to have received preoperative beta-blockade compared to the euthyroid group, while other baseline characteristics were similar between the two groups ( Table 1) . Of the overall group, 44 patients (29.1%) received Lugol's iodine preoperatively. All thyrotoxic patients had a suppressed TSH. The majority of the thyrotoxic group (86%) had an elevated FT3 level (FT3 being the active hormone), 68% had an elevated FT4 level and 55% had both FT4 and FT3 levels elevated. Mild biochemical thyrotoxicosis was present in 40 patients, moderate in 13 patients and severe in three patients. One patient did not have an FT3 result available but FT4 was 1.5 times above the upper limit of the reference interval.
Primary and secondary outcomes are shown in Table 2 . Thirty-day mortality was zero. The only difference between the two groups was a higher use of intraoperative betablockers amongst thyrotoxic patients when compared to euthyroid patients (28.1% versus 8.5%, respectively, P=0.002). Overall, 94% of patients received perioperative dexamethasone for the prevention of postoperative nausea and vomiting (53 patients in the thyrotoxic group and 89 patients in the euthyroid group, P=0.669).
Discussion
There are only two definitive treatment options available for hyperthyroidism-surgery and radioiodine. For some patients, due to medical or social factors, surgery is preferable. Studies assessing the safety of thyroidectomy for thyrotoxicosis have largely focused on the surgical aspect rather than the anaesthetic safety of these patients. Here we report that total thyroidectomy for thyrotoxicosis appears to be safe even in patients with mild to moderate preoperative biochemical thyrotoxicosis. This is consistent with the findings of Shinall et al 6 . The 30-day mortality was zero in both groups and there was no increase in factors that might suggest greater perioperative instability (such as increased need for higher level of care postoperatively or longer hospital stay) when comparing thyrotoxic to euthyroid patients requiring elective surgery for thyrotoxicosis. We did identify increased use of beta-blockers intraoperatively in the thyrotoxic group. This is in keeping with a previous case series which included 70 patients with thyrotoxicosis 6 . The retrospective nature of this study made interpreting the reason for the increased use of beta-blockers difficult. For instance, it is not clear whether the thyrotoxic patients received more intraoperative betablocker because they were more tachycardic or because the anaesthetist had a lower threshold for treating tachycardia knowing that the patient was thyrotoxic. The latter may be suggested by the increase in intraoperative beta-blocker use within the thyrotoxic group, but not in recorded tachycardia (heart rate >100 per minute). Furthermore, it is difficult to determine retrospectively which group had greater intraoperative haemodynamic instability. Haemodynamic stability is affected by the dose of anaesthetic agent, opioid and intravascular fluid volume, therefore without controlling for these factors one cannot accurately interpret *High dependency unit rather than standard general surgical ward; ^planned high dependency unit admission from preoperative assessment in two (comorbidities) and the third due to a postoperative haematoma which required evacuation; #intraoperative thyrotoxicosis was defined as one or more of: HR >100 /minute, systolic blood pressure >180 or <60 mmHg, temperature >38°C.
intraoperative events. As a retrospective observational study, firm conclusions about the safety of anaesthetising hyperthyroid patients for thyroidectomy cannot be determined. However, based on the current study and that of Shinall et al 6 , it could be concluded that anaesthetising thyrotoxic patients for thyroidectomy does not appear to be associated with a high risk of adverse perioperative events, prolonged hospital stay or mortality when thyroid function cannot be normalised.
Limitations of this study include the retrospective nature of the design, which meant we did not have data on clinical assessment of thyrotoxicosis at the time of surgery. However, clinical assessment can be very subjective and the elderly in particular often have fewer signs and symptoms of thyrotoxicosis ('apathetic thyrotoxicosis') with the exception of weight loss and atrial fibrillation 11 . This group of elderly patients may potentially be at higher anaesthetic risk due to underlying comorbidities.
In this study, we included five patients who underwent emergency thyroidectomy, although their presentation and management is not representative of the usual patient being assessed for elective thyroidectomy. Emergency patients were more likely to receive a higher level of postoperative care as planned preoperatively (i.e. planned admission to HDU rather than admission to HDU resulting from medical concerns, which occurred in only one case due to a haematoma requiring evacuation).
These findings need to be confirmed in a larger cohort, and the majority of patients included had only mild or moderate biochemical thyrotoxicosis. These findings may not apply to patients with more severe thyrotoxicosis or those with significant comorbidities, such as symptomatic ischaemic heart disease, in which case optimising thyroid and cardiac status is important prior to considering thyroid surgery.
In addition, a single high-volume thyroid surgeon performed the majority of the thyroid surgery and two anaesthetists experienced in anaesthetising for thyroid surgery administered the anaesthetics. Surgical volume is reported to be associated with improved outcome 12 and so this study may not be applicable to a less experienced surgical and anaesthetic team.
In conclusion, total thyroidectomy for mild to moderate biochemical hyperthyroidism, when performed by an experienced thyroid surgeon and anaesthetist, is associated with increased intraoperative beta-blocker administration, but no statistical difference in mortality, length of postoperative stay or intraoperative thyrotoxicosis. However, despite these findings we still recommend that, whenever possible, patients should be treated medically with the aim for them to be euthyroid at the time of surgery as there may be a reduced safety margin and such patients need to be aware of this when being consented for surgery.
